Results 281 to 289 of about 53,193 (289)
Some of the next articles are maybe not open access.
RET, ROS1 and ALK fusions in lung cancer
Nature Medicine, 2012Through an integrated molecular- and histopathology-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-positive and 13 ROS1-fusion-positive adenocarcinomas, including for unidentified fusion partners for
Kengo, Takeuchi +15 more
openaire +2 more sources
Selective Targeting of RET Fusions in Lung Cancer
Journal of Clinical Oncology, 2023Jessica J. Lin, Justin F. Gainor
openaire +2 more sources
RET Fusion Genes in Thyroid Carcinomas
Endocrine Abstracts, 2022Barbora Pekova +15 more
openaire +1 more source
A Novel Oncogenic RET Fusion Variant in NSCLC: RELCH-RET
Journal of Thoracic Oncology, 2021openaire +2 more sources
Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions.
American health & drug benefitsThis section provides a brief overview of new cancer drugs approved by the FDA between July 24, 2020, and September 4, 2020.
openaire +1 more source
RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer
The Lancet Oncology, 2016Rafael, Rosell, Niki, Karachaliou
openaire +2 more sources